Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Abby Allen

Nurse Practitioner, Family Georgetown, DE Nurse Practitioner

NPI 1497999171 CMS profile 10734717

20797 Professional Park Blvd Ste 214, Georgetown, DE 19947

Open in the dashboard

General payments

$42,708

266 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Abby Allen of Georgetown, DE is reported in the CMS Open Payments database as having received $42,708 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $8,097 38
2023 General $13,843 87
2022 General $9,598 86
2021 General $11,171 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abby Allen
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Abby Allen were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Abby Allen Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $11,171 $124 $35–$379 $132
2022 $9,598 $141 $44–$430 $149
2023 $13,843 $154 $49–$476 $160
2024 $8,097 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AstraZeneca Pharmaceuticals LP $30,265 98 payments
  2. Genentech USA, Inc. $9,497 22 payments
  3. GlaxoSmithKline, LLC. $713 40 payments
  4. Regeneron Healthcare Solutions, Inc. $488 23 payments
  5. Genzyme Corporation $460 20 payments
  6. Novartis Pharmaceuticals Corporation $415 27 payments
  7. Pfizer Inc. $238 8 payments
  8. Amgen Inc. $162 9 payments
  9. Dermavant Sciences, Inc. $100 1 payment
  10. AbbVie, Inc. $84 4 payments
  11. Other $287 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,270 26 payments
  2. Food and Beverage $5,540 217 payments
  3. Travel and Lodging $4,427 18 payments
  4. Consulting Fee $2,404 3 payments
  5. Education $67 2 payments
Products named General payments · program years 2021–2024
  1. FASENRA $18,074 64 payments
  2. Xolair Immunology $9,497 22 payments
  3. TEZSPIRE $8,760 21 payments
  4. DUPIXENT Immunology $868 40 payments
  5. DUPIXENT Inflammation And Immunology $488 23 payments
  6. TRELEGY ELLIPTA $483 25 payments
  7. XOLAIR Respiratory $271 17 payments
  8. XOLAIR Pulmonary/Respiratory Diseases $196 13 payments
  9. NUCALA $190 14 payments
  10. AIRSUPRA $170 3 payments
  11. Other $1,082 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

296

Median for Nurse Practitioner: 389

Drug cost

$67,275

Median for Nurse Practitioner: $21,885

Branded share of claims

24.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xolair Omalizumab Brand 14 $39,175
Breo Ellipta Fluticasone/Vilanterol Brand 24 $15,332
Arnuity Ellipta Fluticasone Furoate Brand 22 $7,324
Ipratropium Bromide Generic 56 $1,947
Fluticasone Propionate Generic 77 $1,856
Azelastine Hcl Generic 11 $473
Famotidine Generic 47 $446
Albuterol Sulfate Hfa Albuterol Sulfate Brand 12 $354
Pantoprazole Sodium Generic 21 $199
Montelukast Sodium Generic 12 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$142,345

Of which drugs: $127,209

Medicare patients

149

Average age 72

Services billed

5,955

94 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Ischemic heart disease 28%
Diabetes 27%
Depression 23%
COPD 21%
Osteoporosis 18%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 18 3,465 $97,443

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Genentech USA, Inc. $5,431
  • Novartis Pharmaceuticals Corporation $65
$5,495 14 3,465
FASENRA
  • AstraZeneca Pharmaceuticals LP $2,015
$2,015 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $151
  • GENZYME CORPORATION $60
  • SANOFI-AVENTIS U.S. LLC $55
$266 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $76
$76 — —
TEZSPIRE
  • Amgen Inc. $41
  • AstraZeneca Pharmaceuticals LP $13
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record